Smart Drugs – Attitudes and public health implications

Smart Drugs (or nootropics) are substances used to enhance cognitive functions. Exact usage numbers are difficult to ascertain, but a recent study conducted among UBC students found that 1 in 30 students admitted using ADHD medication they were not prescribed, for their cognitive effects.

The use of Smart Drugs appears to be gaining momentum in Canada, especially among students and young professionals in high pressure situations, thereby having the potential to turn into a public health issue.

Read More

Use of smart drugs is high particularly among students. A 2013 study of UBC students found that 1 in 3 admitted to obtaining ADHD medication they had not been prescribed, for the purpose of aiding study and the completion of coursework.

Stimulants for treating ADHD are thought to be the most commonly used nootropics, especially among students, because they can be obtained from friends with prescriptions, or possibly by feigning symptoms to obtain a false prescription.

When introduced to the concept of smart drugs, 85% of GPs believed that the marketing materials used to promote smart drugs are perpetuating false information about the benefits of these products; 81% believe they are a significant public health issue; 69% are concerned about safety as it relates to the long terms use of smart drugs. See our infographic for a more detailed look at the results from this study.

Past Quick Polls

COVID-19 Impact on Women in Pharma

The COVID-19 crisis changed the way people work across industries including the pharma industry. MD Analytics teamed up with the professional association for women in the pharma industry Women Leaders in Pharma to conduct a study on the impact on of COVID-19 on women who work in the pharma industry.

read more

Pandemic’s Impact on HCPs Practices and Vaccination Campaign Perceptions

The COVID-19 vaccination campaign is underway in Canada. However, the pandemic has significantly altered HCPs’ practices to date. These changes have impacted workloads, patient assessments, and interactions with pharma. A year into the pandemic, a national COVID-19 vaccination campaign is underway. This begs the question, how are Canadian HCPs doing today? What do they foresee moving forward? Our latest short survey presents the current state of HCPs’ practices in Canada and their assessment of the government’s management of COVID-19.

read more

Remote Detailing for Pharma – Physicians’ perspectives

Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.

read more

We are here to answer your questions.

Share This